Pharma: Moderna-Papiere steigen vorbörslich um fast 60 Prozent – und damit auf den höchsten Stand seit zwei Jahren
Der personalisierte Krebsimpfstoff soll das Wiederauftreten von Melanomen reduzieren. Von der Studie profitiert allerdings nicht nur ein Unternehmen in den USA.
Berlin - Moderna's stock surged nearly 60% before trading started on Wednesday, reaching nearly $100, the highest level since July 2024, following a successful study on a melanoma vaccine, according to Merck. The personalized cancer vaccine Intismeran, combined with Merck's Keytruda cancer medication, is shown to prevent melanoma recurrence.
This marks a significant milestone for mRNA-based therapies, which JPMorgan analysts recently identified as Moderna's most important product. The therapy could help Moderna transition from respiratory illness vaccines to oncology, with the approach currently in nine studies across various cancer indications and stages. US-based company Moderna is reportedly considering the purchase of Biontech facilities.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
